Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The proportion of CBPB users was higher in the osteoporosis group, whereas the proportion of calcium-free phosphate binder, calcimimetics, and PPI users was not significantly different between the groups.Characteristics of the study participants.VariableWhole(n = 321)Osteoporosis(n = 131)Non-osteoporosis(n = 190)P valueDemographicAge, years66 (55 to 72)68 (60 to 74)63 (52 to 70) < 0.001Female, %109 (34)70 (53)39 (21) < 0.001BMI, kg/m222.6 (19.5 to 25.0)20.7 (18.1 to 23.1)23.9 (20.8 to 26.7) < 0.001 < 18.5, %52 (16)36 (28)16 (8) < 0.001 18.5 to 24.9, %190 (59)82 (63)108 (57) ≥ 25, %79 (25)13 (10)66 (35)Dialysis vintage, year9 (5 to 17)10 (5 to 16)8 (4 to 17)0.3Hypertension, %319 (99)130 (99)189 (100)1.0Cardiovascular disease, %138 (43)64 (49)74 (39)0.1Diabetes mellitus, %146 (46)62 (47)84 (44)0.7Laboratory dataAlbumin, g/dL3.6 ± 0.33.6 ± 0.43.6 ± 0.30.5Sodium, mEq/L137.9 ± 3.2137.7 ± 32138.0 ± 3.20.6Calcium, mg/dL8.8 ± 0.58.8 ± 0.58.8 ± 0.60.8Phosphate, mg/dL5.0 ± 1.14.7 ± 1.15.1 ± 1.10.001PTH, pg/mL191 (124 to 283)195 (118 to 288)190 (131 to 282)1.0Kt/V ratios1.5 ± 0.21.6 ± 0.21.4 ± 0.2 < 0.001MedicationCa-based P binders, %251 (78)91 (70)160 (84)0.003Ca-free P binders, %171 (53)61 (47)110 (58)0.1Active vitamin D analog, %247 (77)107 (82)140 (74)0.1Calcimimetic, %186 (58)77 (59)109 (57)0.9PPI, %158 (49)70 (53)88 (46)0.3Data are shown as numbers (percentiles) for categorical variables and mean ± SD or median (interquartile range) for continuous variables.
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a single-center, cross-sectional study on 321 maintenance hemodialysis patients who underwent evaluation of femoral neck BMD using dual-energy X-ray absorptiometry from August 1, 2018, to July 31, 2019.
Source: Abstract.
Patients aged > 80 years or those who lacked routine laboratory data were excluded.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
Cross-sectional study · Scientific Reports · 2021
Original publication title
Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Loss of bone mineral density (BMD) is a substantial risk of mortality in addition to fracture in hemodialysis patients. However, the factors affecting BMD are not fully determined. We conducted a single-center, cross-sectional study on 321 maintenance hemodialysis patients who underwent evaluation of femoral neck BMD using dual-energy X-ray absorptiometry from August 1, 2018, to July 31, 2019. We examined factors associated with osteoporosis defined by T-score of ≤ − 2.5, using logistic regression models. Median age of patients was 66 years, and 131 patients (41%) were diagnosed with osteoporosis.
Older age, female, lower body mass index, diabetes mellitus, and higher Kt/V ratios were associated with higher osteoporosis risk. The only medication associated with lower osteoporosis risk was calcium-based phosphate binders (CBPBs) [odds ratio (OR), 0.41; 95% confidence interval (CI), 0.21 to 0.81]. In particular, CBPB reduced the osteoporosis risk within subgroups with dialysis vintage of ≥ 10 years, albumin level of < 3.5 mg/dL, active vitamin D analog use, and no proton pump inhibitor (PPI) use. In conclusion, CBPB use was associated with lower osteoporosis risk in hemodialysis patients.
This effect might be partially attributable to calcium supplementation, given its higher impact in users of active vitamin D analogs or non-users of PPI, which modulate calcium absorption.
Authors’ abstract
Loss of bone mineral density (BMD) is a substantial risk of mortality in addition to fracture in hemodialysis patients. However, the factors affecting BMD are not fully determined. We conducted a single-center, cross-sectional study on 321 maintenance hemodialysis patients who underwent evaluation of femoral neck BMD using dual-energy X-ray absorptiometry from August 1, 2018, to July 31, 2019. We examined factors associated with osteoporosis defined by T-score of ≤ − 2.5, using logistic regression models. Median age of patients was 66 years, and 131 patients (41%) were diagnosed with osteoporosis.
Older age, female, lower body mass index, diabetes mellitus, and higher Kt/V ratios were associated with higher osteoporosis risk. The only medication associated with lower osteoporosis risk was calcium-based phosphate binders (CBPBs) [odds ratio (OR), 0.41; 95% confidence interval (CI), 0.21 to 0.81]. In particular, CBPB reduced the osteoporosis risk within subgroups with dialysis vintage of ≥ 10 years, albumin level of < 3.5 mg/dL, active vitamin D analog use, and no proton pump inhibitor (PPI) use. In conclusion, CBPB use was associated with lower osteoporosis risk in hemodialysis patients.
This effect might be partially attributable to calcium supplementation, given its higher impact in users of active vitamin D analogs or non-users of PPI, which modulate calcium absorption.
Publication and source details
Original title: Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
Hiroko Hashimoto; Satomi Shikuma; Shintaro Mandai; Susumu Adachi; Shinichi Uchida
Scientific Reports · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T14:39:37.619043+00:00
DOI: 10.1038/s41598-021-81287-4 · PMC7814124